Laura Libonati

Dr. Laura Libonati


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
MCMarco Ceccanti
Marco Ceccanti
VPValeria Pozzilli
Valeria Pozzilli
CCChiara Cambieri
Chiara Cambieri
LLLaura Libonati
Laura Libonati
EOEmanuela Onesti
Emanuela Onesti
MIMaurizio Inghilleri
Maurizio Inghilleri
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with no recognized clinical prognostic factor. Creatinine kinase (CK) increase in these patients is already described with conflicting results on prognosis and survival. In 126 ALS patients who were fast or slow disease progressors, CK levels were assayed for 16 months every 4 months in an observational case-control cohort study with prospective data collection conducted in Italy. CK was also measured at baseline in 88 CIDP patients with secondary axonal damage and in two mouse strains (129SvHSD and C57-BL) carrying the same SOD1G93A transgene expression but showing a fast (129Sv-SOD1G93A) and slow (C57-SOD1G93A) ALS progression rate. Higher CK was found in ALS slow progressors compared to fast progressors in T1, T2, T3, and T4, with a correlation with Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores. Higher CK was found in spinal compared to bulbar-onset patients. Transgenic and non-transgenic C57BL mice showed higher CK levels compared to 129SvHSD strain. At baseline mean CK was higher in ALS compared to CIDP. CK can predict the disease progression, with slow progressors associated with higher levels and fast progressors to lower levels, in both ALS patients and mice. CK is higher in ALS patients compared to patients with CIDP with secondary axonal damage; the higher levels of CK in slow progressors patients, but also in C57BL transgenic and non-transgenic mice designs CK as a predisposing factor for disease rate progression.

24 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
CCChiara Cambieri
Chiara Cambieri
LLLaura Libonati
Laura Libonati
FMFederica Moret
Federica Moret
GTGiorgio Tartaglia
Giorgio Tartaglia
MGMatteo Garibaldi
Matteo Garibaldi
MCMarco Ceccanti
Marco Ceccanti
Background: Transthyretin-mediated amyloidosis (ATTR) is a rare multisystemic disease involving the peripheral nervous system and heart. Autonomic and small fiber involvement is one of the hallmarks of ATTR, and many tools have been proposed to assess this aspect. Aim: The aim of this study was to investigate cutaneous and mixed nerve silent periods (CSP and MnSP) as instruments for small fiber assessment. Methods: A total of 21 ATTR patients, 20 healthy controls, and 18 asymptomatic carriers underwent a sensory conduction study from the right sural and non-dominant ulnar nerves. A motor conduction study from the right deep peroneal and non-dominant ulnar nerves, with their F waves, CSPs, and MnSPs, was performed. Results: The amplitudes of the sural and ulnar sensory nerves and of the peroneal and ulnar motor nerves were reduced in ATTR patients compared to the other groups. F waves from the ulnar and peroneal nerves showed no differences between the three groups. The CSP and MnSP latency, but not amplitude, were increased in both the ulnar and peroneal nerves of ATTR patients. Conclusions: ATTR patients showed axonal involvement of large sensory and motor nerve fibers and demyelinating features of small sensory fibers.

18 January 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
LLLaura Libonati
Laura Libonati
IFIlenia Fiorini
Ilenia Fiorini
CCChiara Cambieri
Chiara Cambieri
MCMarco Ceccanti
Marco Ceccanti
MIMaurizio Inghilleri
Maurizio Inghilleri